Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 15/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | GAA | P10253 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | XBP1 | P17861 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498138 | 0.97 | RAD51 (0.95) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL30044879 | 0.95 | RAD51 (1.00) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL23511142 | 0.95 | RAD51 (1.00) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL23498211 | 0.95 | RAD51 (1.00) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL23498259 | 0.94 | RAD51 (1.00) | RAD51KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL16339173 | 0.91 | RAD51 (1.00) | RAD51KDM4EALDH1A1GAA | |
| SCHEMBL30043447 | 0.90 | RAD51 (1.00) | RAD51 | |
| SCHEMBL23498096 | 0.90 | RAD51 (1.00) | RAD51 | |
| SCHEMBL23498136 | 0.89 | RAD51 (1.00) | RAD51KDM4EALDH1A1GAA | |
| SCHEMBL23498095 | 0.89 | RAD51 (1.00) | RAD51 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| EP-4073054-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | Fondazione Istituto Italiano di Tecnologia (IT) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | RAD51, BRCA1, FANCI | RAD51 1/4885KDM4E 4394/4885ALDH1A1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.